Analysts Set Gyre Therapeutics, Inc. (NASDAQ:GYRE) Target Price at $17.00

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) have received an average rating of “Hold” from the five ratings firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $17.00.

GYRE has been the subject of several research analyst reports. Zacks Research raised Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, November 14th. Weiss Ratings reiterated a “sell (d)” rating on shares of Gyre Therapeutics in a report on Wednesday, October 8th. HC Wainwright initiated coverage on shares of Gyre Therapeutics in a research note on Tuesday, August 26th. They issued a “buy” rating and a $18.00 price objective on the stock. Jefferies Financial Group started coverage on shares of Gyre Therapeutics in a research report on Friday, October 10th. They set a “buy” rating and a $16.00 target price on the stock. Finally, Wall Street Zen raised shares of Gyre Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 15th.

Gyre Therapeutics Price Performance

Shares of GYRE opened at $7.69 on Wednesday. The company has a market capitalization of $740.78 million, a PE ratio of 256.42 and a beta of 1.96. Gyre Therapeutics has a one year low of $6.11 and a one year high of $14.42. The company’s fifty day moving average price is $7.84 and its 200 day moving average price is $7.77.

Institutional Trading of Gyre Therapeutics

Several hedge funds have recently modified their holdings of GYRE. Bank of America Corp DE lifted its position in Gyre Therapeutics by 28.8% during the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock worth $46,000 after buying an additional 1,402 shares in the last quarter. Alliancebernstein L.P. raised its stake in shares of Gyre Therapeutics by 9.5% in the third quarter. Alliancebernstein L.P. now owns 21,830 shares of the company’s stock worth $163,000 after acquiring an additional 1,900 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Gyre Therapeutics by 84.6% during the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after purchasing an additional 2,961 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Gyre Therapeutics by 77.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after purchasing an additional 3,244 shares during the last quarter. Finally, Advantage Alpha Capital Partners LP grew its stake in shares of Gyre Therapeutics by 54.0% during the first quarter. Advantage Alpha Capital Partners LP now owns 13,663 shares of the company’s stock valued at $105,000 after purchasing an additional 4,790 shares during the last quarter. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.